|Videos|October 19, 2021
Role of Telemedicine in Bipolar Disorder
Michael E. Thase, MD; Theresa Cerulli, MD; Gustavo Alva, MD, DFAPA; and Tina Matthews-Hayes, DNP, FNP, PMHNP, provide insight on the role of telemedicine in improving outcomes for patients with bipolar disorder.
Advertisement
Episodes in this series
Advertisement
Related to this article
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
5